default author photo

Sadna Budhu

Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program

United States

SCHOLARLY PAPERS

3

DOWNLOADS

218

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Targeting Phosphatidylserine Enhances the Anti-Tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma

Number of pages: 57 Posted: 03 Sep 2019
Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Department of Medicine and Memorial Sloan Kettering Cancer Center - Department of Medicine
Downloads 107 (654,668)

Abstract:

Loading...

phosphatidylserine, radiation therapy, PD-1, melanoma, immunotherapy, immune modulation

2.

T Cell Immunotherapies Trigger Neutrophil Activation to Eliminate Tumor Antigen Escape Variants

Number of pages: 39 Posted: 26 May 2020
Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center - Department of Medicine, Parker Institute for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Department of Pathology, Parker Institute for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center - Department of Pathology, Memorial Sloan Kettering Cancer Center - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center - Department of Epidemiology and Biostatistics, University of California, San Francisco (UCSF) - Department of Pathology, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory, Memorial Sloan Kettering Cancer Center - Ludwig Collaborative and Swim Across America Laboratory and Memorial Sloan Kettering Cancer Center - Ludwig Collaborative and Swim Across America Laboratory
Downloads 82 (790,029)

Abstract:

Loading...

tumor immunology, tumor heterogeneity, Immune checkpoint blockade, T cell costimulation, Neutrophils, innate immunity

3.

Preoperative Immune Checkpoint Inhibition and Cryoablation in Early-Stage Breast Cancer

Number of pages: 95 Posted: 27 Jan 2022
Memorial Sloan Kettering Cancer Center - Breast Medicine Service, Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center - Computational Oncology Service, Providence Cancer Center - Earle A. Chiles Research Institute, Memorial Sloan Kettering Cancer Center - Immune Monitoring Core Facility, Memorial Sloan Kettering Cancer Center - Immune Monitoring Core Facility, Memorial Sloan Kettering Cancer Center - Immune Monitoring Core Facility, Memorial Sloan Kettering Cancer Center - Breast Surgery, Memorial Sloan Kettering Cancer Center - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center - Department of Pathology, Memorial Sloan Kettering Cancer Center - Department of Radiology, Memorial Sloan Kettering Cancer Center - Department of Radiology, Memorial Sloan Kettering Cancer Center - Department of Radiology, Memorial Sloan Kettering Cancer Center - Breast Medicine Service, Memorial Sloan Kettering Cancer Center - Ludwig Collaborative and Swim Across America Laboratory and Memorial Sloan Kettering Cancer Center - Breast Medicine Service
Downloads 29 (1,332,057)

Abstract:

Loading...

Breast cancer, cryoablation, checkpoint inhibition, early-stage, ipilimumab, nivolumab, resectable